PNK CD16VP
Alternative Names: PNK-CD16VP; PNK-CD16VP + mAbLatest Information Update: 28 Jul 2024
At a glance
- Originator Celularity
- Class Antineoplastics; Gene therapies; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 28 Jan 2024 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)
- 24 Jul 2020 Celularity has patents pending for genetically modified natural killer cells based on CD16 variant